Apoptosis is a form of regulated cell death (RCD) that involves proteases of the caspase
family. Pharmacological and genetic strategies that experimentally inhibit or delay apoptosis …

Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …

Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …

Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

Herein, we present the long-term follow-up of the randomized E1912 trial comparing the
long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and …

Background Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with
efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …

For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Background Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with
activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or …

PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal
residual disease (MRD)-guided treatment discontinuation following completion of first-line …